Thomas P. O'Neil is CFO at Satsuma Pharmaceuticals, Inc. (STSA). They have made 3 open-market trades across 2 companies since 2017, most recently 2023-06-06.
CIK 0001640645
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STSA | SELL · 10b5-1 | 2020-09-01 | 2020-09-03 | $22.19 | $17K | -79.6% | -83.1% | -80.1% |
| STSA | SELL · 10b5-1 | 2020-08-05 | 2020-08-07 | $25.00 | $25K | -4.5% | -11.2% | -84.0% |
| STSA | SELL · 10b5-1 | 2020-07-01 | 2020-07-02 | $26.65 | $27K | +2.4% | -17.3% | -86.0% |
| STSA | SELL | 2020-06-23 | 2020-06-24 | $35.23 | $149K | -10.1% | -17.7% | -86.1% |
| STSA | SELL · 10b5-1 | 2020-06-01 | 2020-06-02 | $25.32 | $25K | +6.1% | +7.2% | -9.4% |
| STSA | SELL | 2020-05-20 | 2020-05-21 | $25.00 | $50K | +0.2% | +31.9% | -8.1% |
| STSA | SELL · 10b5-1 | 2020-03-11 | 2020-03-12 | $27.68 | $28K | -4.5% | +5.3% | +58.3% |
| PTGX | SELL | 2017-12-18 | 2017-12-20 | $20.00 | $160K | +9.0% | -1.5% | +6.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.